Bridgebio Pharma Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect three (3) Class I director nominees—James C. Momtazee, Frank P. McCormick, Ph.D., F.R.S., D.Sc., and Hannah A. Valantine, M.D.—to serve until the 2028 annual meeting.

2. 2

   Non-Binding, Advisory Vote to Approve the Compensation of our Named Executive Officers ("Say-on-Pay

   ManagementBoard: FOR

   Non-binding, advisory approval of the compensation of the Company’s named executive officers as disclosed in the proxy statement (Compensation Discussion and Analysis, tables and narrative).

   More detail

   This non-binding advisory proposal asks shareholders to approve the Company’s named executive officer (NEO) compensation disclosure and overall compensation approach. Management seeks this approval to validate its pay-for-performance philosophy and the specific 2025 compensation program, which included substantial ‘at-risk’ elements (stock options, RSUs, and newly introduced PSUs) and discretionary cash bonuses tied to corporate and individual performance. The filing emphasizes steps taken in response to prior shareholder feedback—introducing PSUs, moderating base salary increases, adopting stock ownership guidelines, and targeted engagement with large holders—framing the program as more aligned with stockholder interests. The vote is advisory and non-binding, so while the Board will consider the outcome in future decisions, it retains discretion over pay decisions. The Company highlights strong 2025 operational achievements (product approvals, positive Phase 3 readouts and commercial uptake) as supporting rationale for the compensation outcomes. From a governance perspective, the Compensation Committee retained an independent consultant, used a peer group and multiple metrics, and incorporated clawback and anti-hedging policies to mitigate risk and align incentives. A Yes vote signals investor support for the program design and management’s execution; a No vote would likely prompt further engagement and potential revisions to plan design. Analysts evaluating this proposal should weigh the Company’s recent clinical and commercial progress, the high percentage of pay that is performance-based, the introduction of PSUs tied to specific clinical readouts, and investor outreach that preceded the 2025 decisions in assessing whether pay outcomes are appropriately linked to long-term value creation.

3. 3

   Non-Binding, Advisory Vote on the Frequency of Future Non-Binding Advisory Votes to Approve the Compensation of our Named Executive Officers ("Say-on-Frequency

   ManagementBoard: FOR

   Advisory vote where shareholders indicate whether future advisory votes on NEO compensation should occur every one, two, or three years; the Board recommends holding the vote every one year.

   More detail

   This advisory proposal asks shareholders to indicate their preferred frequency for future say-on-pay advisory votes: one, two, or three years. Management and the Board prefer an annual (one-year) vote, arguing it enables timely, regular feedback and supports ongoing shareholder engagement on compensation matters. The Board’s recommendation reflects its view that annual votes facilitate a closer, iterative dialogue with investors and allow quicker responsiveness to concerns, which is particularly relevant given recent shareholder engagement on compensation design. Opponents of annual frequency typically argue that annual votes can lead to short-termism, increase administrative burden and costs, and that triennial votes align better with long-term incentive cycles; proponents counter that advisory votes are non-binding and the benefit of continuous feedback outweighs those costs. For BridgeBio specifically, the Board points to recent changes—introduction of PSUs, stock ownership guidelines, and targeted outreach—that suggest ongoing engagement is active and useful. Investors evaluating the proposal should consider the company’s cadence of strategic milestones, the pace at which compensation philosophy and awards change, and whether annual feedback materially improves governance outcomes. A choice of ‘one year’ would maintain the status quo; a different choice could signal investor preference for less frequent input and potentially more stable compensation cycles.

4. 4

   Ratification of the Selection of the Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

5. 5

   Approval of an Amendment and Restatement of the 2021 Stock Option and Incentive Plan to Increase Reserved Shares by 2,000,000

   ManagementBoard: FOR

   Approve the Third Amended and Restated 2021 Plan to increase the aggregate number of shares authorized for issuance under the plan by 2,000,000 shares (including incentive stock option capacity).

   More detail

   This management proposal requests shareholder approval of a third amendment and restatement to the Company’s 2021 Stock Option and Incentive Plan to add 2,000,000 shares to the pool available for equity awards (including incentive stock options). Management argues the increase is necessary to continue to attract, retain and motivate employees, consultants and directors, emphasizing that equity is a central component of compensation and alignment with stockholders. The filing provides context: a three‑year net annual burn rate (2023–2025) of about 3.7%, year‑end overhang roughly in the mid‑teens, and that the contemplated increase represents roughly 1% of outstanding shares at year‑end, with total overhang remaining modest and within institutional investor thresholds. The proposed plan contains standard governance protections—award recycling for forfeitures, anti‑repricing without stockholder approval, annual limits for non‑employee director compensation, clawback provisions and no automatic annual increases—intended to limit dilution and protect stockholder interests. Management also explains alternative steps if the proposal fails (cash incentives or restricted participation), which could increase cash burn or impair retention and alignment. For investors assessing the proposal, key considerations include the reasonableness of the requested quantum relative to historical burn and hiring plans, the Company’s operating cash needs versus equity expense, and whether the plan’s governance features sufficiently mitigate dilution risk. Approval would preserve management’s flexibility to grant equity necessary for business execution and talent retention; rejection would force the Board to adopt other, potentially less attractive, compensation measures or seek a different share increase later.

Upcoming shareholder meetings at Bridgebio Pharma Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Bridgebio Pharma Inc 2026 annual meeting?

Bridgebio Pharma Inc (BBIO) holds its 2026 annual shareholder meeting on Monday, June 22, 2026.

What is the record date for the Bridgebio Pharma Inc 2026 meeting?

The record date for the Bridgebio Pharma Inc 2026 meeting is Thursday, April 23, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Bridgebio Pharma Inc's 2026 meeting?

The board is presenting 3 director nominees at the Bridgebio Pharma Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Bridgebio Pharma Inc 2026 meeting?

Shareholders will vote on 5 proposals at the Bridgebio Pharma Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.